This CE activity was originally published in The Rx Consultant. If you received credit for it previously, you cannot receive credit for it again.
Several approaches to cholesterol management have traditionally been used, including "treat-to-target" and "lower is better." In 2001, the National Cholesterol Education Program (NCEP) issued a guideline on cholesterol management that was most recently updated in 2004. The guideline set specific LDL targets for treatment in different risk groups. In November of 2013, the American College of Cardiology and the American Heart Association (ACC/AHA) published an updated cholesterol guideline to help providers reduce the overall risk for atherosclerotic cardiovascular disease (ASCVD). As in the previous guideline, lifestyle measures such as a heart-healthy diet, regular exercise, avoiding tobacco products, and maintaining a healthy weight remain the foundation for risk reduction (see the Patient Connection). However, the 2013 recommendations for drug treatment (specifically, statin use) represent a paradigm shift. The 2013 guideline features the elimination of LDL and non-HDL treatment targets; the identification of 4 statin benefit groups with corresponding recommendations for the intensity of statin treatment; the introduction of a new cardiovascular (CV) risk assessment calculator, to estimate 10-year ASCVD risk; and safety recommendations, including management of statin side effects. The new guideline has been the subject of intense controversy.
This issue of The Rx Consultant presents the guideline’s background, its key recommendations for treatment and for safety monitoring, and a discussion of the controversy it caused. You'll also find additional statin information (updated since our 2006 issue) including key differences among agents.
This CE activity is a monograph (PDF file).
Pharmacists, Nurse Practitioners, Clinical Nurse Specialists, and Registered Nurses
This CE activity was developed by The Rx Consultant, a publication of Continuing Education Network, Inc.
CE activities for Pharmacists and Pharmacy Technicians:
This continuing education (CE) activity meets the requirements of all state boards of pharmacy for approved continuing education hours. CE credit is automatically reported to CPE Monitor.
CE activities for Nurse Practitioners and Clinical Nurse Specialists:
This continuing education activity meets the requirements of:
The American Nurses Credentialing Center (ANCC) for formally approved continuing education (CE) hours, and CE hours of pharmacotherapeutics.
The American Academy of Nurse Practitioners Certification Program (AANPCP) for acceptable, accredited CE.
This is a pharmacotherapeutics/pharmacology CE activity.
The ANCC requires all advanced practice nursing certificants (CNSs and NPs) to complete 25 CE hours of pharmacotherapeutics as a portion of the required 75 continuing education hours.
Pharmacology CE is recommended by the AANPCP and will be required for Certificants renewing certification starting January 2017.
Most State Boards of Nursing require a minimum number of pharmacy contact hours to renew an advanced practice license.
Continuing Education Network, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Requirements for CE Credit
CE No Longer Valid
Pharmacists and Pharmacy Technicians -
Be sure your profile has been updated with your NAPB e-profile # and birth date informationBEFORE completing the online evaluation, or your credits cannot be reported to CPE Monitor.
Continuing pharmacy education credit is automatically reported to CPE Monitor once the post-test & evaluation are successfully completed.
Outline the main differences between the 2013 ACC /AHA cholesterol management guideline and the previous NCEP guideline. Discuss the controversy about the new guideline.
Describe the 4 statin benefit groups identified in the 2013 guideline, and the recommended intensity of statin therapy for each. List at least 2 regimens of each intensity.
Discuss monitoring for statin response and adverse effects. Provide 1-2 patient counseling tips about myopathy, liver dysfunction, cognitive impairment and new-onset diabetes.
List at least 3 drug interactions that may affect statin levels and/or increase the risk of myopathy.
Jessica M. Downes
Brief Bio : Jessica M. Downes, PharmD, Post-Graduate Year Two Ambulatory Care Resident, University of Oklahoma, Tulsa, OK.
Disclosure : Dr. Downes reports no financial or personal relationship with any commercial interest producing, marketing, reselling, or distributing a product or service that appears in this issue.
Kelsey T. Lackey
Brief Bio : Kelsey T. Lackey, PharmD, BCPS, Post-Graduate Year Two Ambulatory Care Resident, University of Oklahoma, Tulsa, OK.
Disclosure : Dr. Lackey reports no financial or personal relationship with any commercial interest producing, marketing, reselling, or distributing a product or service that appears in this issue.
Michelle M. Lamb
Brief Bio : Michelle M. Lamb, PharmD, CDE, BCACP, Clinical Assistant Professor, University of Oklahoma College of
Disclosure : Dr. Lamb reports no financial or personal relationship with any commercial interest producing, marketing, reselling, or distributing a product or service that appears in this issue.